Cargando…
Levamisole as an Adjuvant to Short-Course Therapy in Newly Diagnosed Pulmonary Tuberculosis Patients
BACKGROUND: The estimated incidence and prevalence of tuberculosis in India are 2.1 and 2.6 million cases respectively. Immunotherapy may shorten tuberculosis treatments and improve the immunity of individuals as well. Hence we study the efficacy of levamisole (LVM) (immunomodulator) as an adjuvant...
Autores principales: | Shamkuwar, Chetna Ashok, Meshram, Sushant Hiraman, Mahakalkar, Sunil M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5385702/ https://www.ncbi.nlm.nih.gov/pubmed/28516071 http://dx.doi.org/10.4103/2277-9175.203162 |
Ejemplares similares
-
Late mortality and levamisole adjuvant therapy in colorectal cancer.
por: Chlebowski, R. T., et al.
Publicado: (1994) -
Clinical response of newly diagnosed HIV seropositive & seronegative pulmonary tuberculosis patients with the RNTCP Short Course regimen in Pune, India
por: Tripathy, S., et al.
Publicado: (2011) -
N-acetylcysteine as an add-on to Directly Observed Therapy Short-I therapy in fresh pulmonary tuberculosis patients: A randomized, placebo-controlled, double-blinded study
por: Mahakalkar, Sunil M., et al.
Publicado: (2017) -
Adjuvant 5-fluorouracil plus levamisole in colon cancer: the plot thickens?
por: Cassidy, J.
Publicado: (1994) -
Levamisole Usage as an Adjuvant to Hepatitis B Vaccine in Hemodialysis Patients, Yes or No?
por: Sanadgol, Houshang
Publicado: (2012)